The Epidemiology of Breast Implant-Associated Anaplastic Large Cell Lymphoma in Australia and New Zealand Confirms the Highest Risk for Grade 4 Surface Breast Implants.
Adult
Aged
Australia
/ epidemiology
Breast Implantation
/ adverse effects
Breast Implants
/ adverse effects
Female
Humans
Lymphoma, Large-Cell, Anaplastic
/ epidemiology
Middle Aged
New Zealand
/ epidemiology
Polyurethanes
/ toxicity
Postoperative Complications
/ epidemiology
Risk Assessment
Surface Properties
Young Adult
Journal
Plastic and reconstructive surgery
ISSN: 1529-4242
Titre abrégé: Plast Reconstr Surg
Pays: United States
ID NLM: 1306050
Informations de publication
Date de publication:
05 2019
05 2019
Historique:
pubmed:
23
2
2019
medline:
23
5
2019
entrez:
22
2
2019
Statut:
ppublish
Résumé
The epidemiology and implant-specific risk for breast implant-associated (BIA) anaplastic large cell lymphoma (ALCL) has been previously reported for Australia and New Zealand. The authors now present updated data and risk assessment since their last report. New cases in Australia and New Zealand were identified and analyzed. Updated sales data from three leading breast implant manufacturers (i.e., Mentor, Allergan, and Silimed) were secured to estimate implant-specific risk. A total of 26 new cases of BIA-ALCL were diagnosed between January of 2017 and April of 2018, increasing the total number of confirmed cases in Australia and New Zealand to 81. This represents a 47 percent increase in the number of reported cases over this period. The mean age and time to development remain unchanged. The implant-specific risk has increased for Silimed polyurethane (23.4 times higher) compared with Biocell, which has remained relatively static (16.5 times higher) compared with Siltex implants. The number of confirmed cases of BIA-ALCL in Australia and New Zealand continues to rise. The implant-specific risk has now changed to reflect a strong link to implant surface area/roughness as a major association with this cancer.
Sections du résumé
BACKGROUND
The epidemiology and implant-specific risk for breast implant-associated (BIA) anaplastic large cell lymphoma (ALCL) has been previously reported for Australia and New Zealand. The authors now present updated data and risk assessment since their last report.
METHODS
New cases in Australia and New Zealand were identified and analyzed. Updated sales data from three leading breast implant manufacturers (i.e., Mentor, Allergan, and Silimed) were secured to estimate implant-specific risk.
RESULTS
A total of 26 new cases of BIA-ALCL were diagnosed between January of 2017 and April of 2018, increasing the total number of confirmed cases in Australia and New Zealand to 81. This represents a 47 percent increase in the number of reported cases over this period. The mean age and time to development remain unchanged. The implant-specific risk has increased for Silimed polyurethane (23.4 times higher) compared with Biocell, which has remained relatively static (16.5 times higher) compared with Siltex implants.
CONCLUSIONS
The number of confirmed cases of BIA-ALCL in Australia and New Zealand continues to rise. The implant-specific risk has now changed to reflect a strong link to implant surface area/roughness as a major association with this cancer.
Identifiants
pubmed: 30789476
doi: 10.1097/PRS.0000000000005500
pii: 00006534-201905000-00001
doi:
Substances chimiques
Polyurethanes
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1285-1292Commentaires et corrections
Type : CommentIn
Type : CommentIn
Type : CommentIn
Références
Clemens MW, Brody GS, Mahabir RC, Miranda RN. How to diagnose and treat breast implant-associated anaplastic large cell lymphoma. Plast Reconstr Surg. 2018;141:586e–599e.
Hopper I, Ahern S, McNeil JJ, et al. Improving the safety of breast implants: Implant-associated lymphoma. Med J Aust. 2017;207:185–186.
Loch-Wilkinson A, Beath KJ, Knight RJW, et al. Breast implant-associated anaplastic large cell lymphoma in Australia and New Zealand: High-surface-area textured implants are associated with increased risk. Plast Reconstr Surg. 2017;140:645–654.
de Boer M, van Leeuwen FE, Hauptmann M, et al. Breast implants and the risk of anaplastic large-cell lymphoma in the breast. JAMA Oncol. 2018;4:335–341.
Doren EL, Miranda RN, Selber JC, et al. U.S. epidemiology of breast implant-associated anaplastic large cell lymphoma. Plast Reconstr Surg. 2017;139:1042–1050.
McGuire P, Reisman NR, Murphy DK. Risk factor analysis for capsular contracture, malposition, and late seroma in subjects receiving Natrelle 410 form-stable silicone breast implants. Plast Reconstr Surg. 2017;139:1–9.
Jones P, Mempin M, Hu H, et al. The functional influence of breast implant outer shell morphology on bacterial attachment and growth. Plast Reconstr Surg. 2018;142:837–849.
Magnusson MR, Deva AK. Letter to Editor: Fleming D, Stone J, Tansley P. Spontaneous regression and resolution of breast implant-associated anaplastic large cell lymphoma: Implications for research, diagnosis and clinical management, APS 2018. Aesthetic Plast Surg. 2018;42:1164–1166.
Jacombs A, Tahir S, Hu H, et al. In vitro and in vivo investigation of the influence of implant surface on the formation of bacterial biofilm in mammary implants. Plast Reconstr Surg. 2014;133:471e–480e.
Hu H, Jacombs A, Vickery K, Merten SL, Pennington DG, Deva AK. Chronic biofilm infection in breast implants is associated with an increased T-cell lymphocytic infiltrate: Implications for breast implant-associated lymphoma. Plast Reconstr Surg. 2015;135:319–329.
Ashley FL. Further studies on the natural-Y breast prosthesis. Plast Reconstr Surg. 1972;49:414–419.
Ashley FL. A new type of breast prosthesis: Preliminary report. Plast Reconstr Surg. 1970;45:421–424.
Chan SC, Birdsell DC, Gradeen CY. Urinary excretion of free toluenediamines in a patient with polyurethane-covered breast implants. Clin Chem. 1991;37:2143–2145.
Chan SC, Birdsell DC, Gradeen CY. Detection of toluenediamines in the urine of a patient with polyurethane-covered breast implants. Clin Chem. 1991;37:756–758.
Sepai O, Henschler D, Czech S, Eckert P, Sabbioni G. Exposure to toluenediamines from polyurethane-covered breast implants. Toxicol Lett. 1995;77:371–378.
Hester TR Jr, Ford NF, Gale PJ, et al. Measurement of 2,4-toluenediamine in urine and serum samples from women with Même or Replicon breast implants. Plast Reconstr Surg. 1997;100:1291–1298.
Handel N, Gutierrez J. Long-term safety and efficacy of polyurethane foam-covered breast implants. Aesthet Surg J. 2006;26:265–274.
Castel N, Soon-Sutton T, Deptula P, Flaherty A, Parsa FD. Polyurethane-coated breast implants revisited: A 30-year follow-up. Arch Plast Surg. 2015;42:186–193.
Bhatt AP, Redinbo MR, Bultman SJ. The role of the microbiome in cancer development and therapy. CA Cancer J Clin. 2017;67:326–344.
Wang L, Ganly I. The oral microbiome and oral cancer. Clin Lab Med. 2014;34:711–719.
Yang J, Tan Q, Fu Q, et al. Gastrointestinal microbiome and breast cancer: Correlations, mechanisms and potential clinical implications. Breast Cancer 2017;24:220–228.
Borghi A, Caselli E, Di Luca D, et al. Detection of Chlamydophila pneumoniae and human herpesvirus 8 in primary cutaneous anaplastic large-cell lymphoma: A case report. Infect Agent Cancer 2013;8:41.
Caselli E, Borghi A, Maritati M, et al. Relapses of primary cutaneous anaplastic large-cell lymphoma in a female immunocompetent patient with persistent chlamydophila pneumoniae and human herpesvirus 8 infection. Infect Agent Cancer 2016;11:31.
Wolk K, Mitsui H, Witte K, et al. Deficient cutaneous antibacterial competence in cutaneous T-cell lymphomas: Role of Th2-mediated biased Th17 function. Clin Cancer Res. 2014;20:5507–5516.
Webb LH, Aime VL, Do A, Mossman K, Mahabir RC. Textured breast implants: A closer look at the surface debris under the microscope. Plast Surg (Oakv.) 2017;25:179–183.
Moss SF, Blaser MJ. Mechanisms of disease: Inflammation and the origins of cancer. Nat Clin Pract Oncol. 2005;2:90–97; quiz 1 p following 113.
Manning CB, Vallyathan V, Mossman BT. Diseases caused by asbestos: Mechanisms of injury and disease development. Int Immunopharmacol. 2002;2:191–200.
Ding M, Chen F, Shi X, Yucesoy B, Mossman B, Vallyathan V. Diseases caused by silica: Mechanisms of injury and disease development. Int Immunopharmacol. 2002;2:173–182.
Malcolm TI, Hodson DJ, Macintyre EA, Turner SD. Challenging perspectives on the cellular origins of lymphoma. Open Biol. 2016;6:160232.
Hopper I, Ahern S, Nguyen TQ, et al. Breast implant registries: A call to action. Aesthet Surg J. 2018;38:807–810.
Cooter R, Barnett R, Deva A, et al. In defense of the International Collaboration of Breast Registry Activities (ICOBRA). Aesthet Surg J. 2016;36:NP225–NP227.